Bristol-Myers Squibb Company ( BMY Quick Quote BMY - Free Report) announced that it entered a global license agreement with clinical-stage immuno-oncology company, Agenus ( AGEN Quick Quote AGEN - Free Report) .
Per the agreement, Bristol Myers Squibb will obtain a global exclusive license to the latter’s proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
Bristol Myers will be entirely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. In exchange, Agenus will receive an upfront payment of $200 million and up to $1.36 billion in development, regulatory and commercial milestones, in addition to tiered double-digit royalties on net product sales. It will also retain options to conduct clinical studies under the development plan, combination studies with certain other Agenus pipeline assets and co-promote AGEN1777 in the United States, upon commercialization.
We note that Agenus expects to file an Investigational New Drug (“IND”) application for the development of AGEN1777 with the FDA in the second quarter. Bristol Myers intends to advance the research and development of AGEN1777 in immuno-oncology (“I-O”) for high-priority tumor indications, including non-small cell lung cancer.
AGEN1777 is in late preclinical development and designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies, this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.
Shares of Agenus rallied 20.5% on the news.
Meanwhile, Bristol-Myers’ shares have gained 5.7% year to date against the
industry's decline of 5.4%.
The company’s performance in the first quarter of 2021 was dismal as Opdivo sales declined. Moreover, Revlimid sales weren’t impressive either.
Nevertheless, the recent approval of new drugs adds a new stream of revenues, which should propel growth in the coming quarters.
In March, the company and partner
bluebird bio, Inc. ( BLUE Quick Quote BLUE - Free Report) obtained the FDA approval for Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory MM. The FDA also approved Breyanzi (lisocabtagene maraleucel: liso-cel), a CD19-directed CAR T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma.
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector includes
Repligen Corporation ( RGEN Quick Quote RGEN - Free Report) , which carries a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Repligen’s earnings estimates for 2021 have increased to $2.21 from $1.66 in the past 90 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>